Nano-X Imaging is especially popular with analysts. Recursion Pharmaceuticals plans to report results from seven clinical studies over the next 18 months.
Here is how Nano-X Imaging Ltd. (NNOX) and Parsons (PSN) have performed compared to their sector so far this year.
Here is how Nano-X Imaging Ltd. (NNOX) and Seagate (STX) have performed compared to their sector so far this year.
NanoX Imaging (NNOX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
NanoX Imaging (NNOX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Here is how Nano-X Imaging Ltd. (NNOX) and Deluxe (DLX) have performed compared to their sector so far this year.
Nano-X Imaging stock rallied in February, but it's still down by about half over the past year. The FDA approved the company's flagship device over a year ago, but sales have been disappointing.
Nano-X Imaging Ltd. (NASDAQ:NNOX ) Q1 2024 Earnings Conference Call May 28, 2024 8:30 AM ET Company Participants Mike Cavanaugh - Investor Relations Erez Meltzer - Chief Executive Officer Ran Daniel - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Jeff Cohen - Ladenburg Thalmann Operator Good day and thank you for standing by.